# Preclinical Assessment of an Engineered HMGB1 Protein as a Novel Companion Therapy for Muscular Dystrophies

> **NCT07745218** · — · RECRUITING · sponsor: **IRCCS San Raffaele** · enrollment: 25 (estimated)

## Conditions studied

- LAMA2-MD (Merosin Deficient Congenital Muscular Dystrophy, MDC1A)

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07745218
- **Lead sponsor:** IRCCS San Raffaele
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2026-08-01
- **Primary completion:** 2029-07
- **Final completion:** 2029-07
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2026-08-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07745218

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07745218, "Preclinical Assessment of an Engineered HMGB1 Protein as a Novel Companion Therapy for Muscular Dystrophies". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07745218. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*